Congressionally Directed Medical Research Programs (CDMRP) Ovarian Cancer Research Program Funding Opportunities for Fiscal Year 2023 (FY23)

How to Apply: 

The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their family members, and all women impacted by this disease.  The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY23 OCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

 

Applications submitted to the FY23 OCRP must address one or more of the following Areas of Emphasis:

  • Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomics and other critical events
  • Develop novel therapeutic strategies for treatment and prevention
  • Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis, and prognosis
  • Identify and implement strategies to improve the survivorship and quality of life
  • Address health disparities
  • Improve precision medicine

 

Alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. Justification must be provided in the application.

 

https://cdmrp.health.mil/funding/ocrp

 

Clinical Trial Award – Letter of Intent due May 26, 2023

Independent investigators at all academic levels.

Supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer.

Proposed projects may range from small, proof-of-concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1, or 1/2).

Preliminary data are required. Larger, more-definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population.

•The maximum allowable funding for the entire period of performance is $2,000,000 for direct costs.

•Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•The maximum period of performance is 4 years.

 

 

NEW! Clinical Translational Research Award – Letter of Intent due May 26, 2023

The Principal Investigator (PI) must be at or above the level of Assistant Professor (or equivalent).

Supports correlative studies that address translational research in high-impact or unmet needs in ovarian cancer and have a clinical emphasis. 

•Applications focused on the following OCRP priority are encouraged:

‒Utilize precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.

•Clinical trials are not allowed.

•The maximum allowable funding for the entire period of performance is $2,000,000 for direct costs.

•Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•The maximum period of performance is 4 years.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBRAP.org

 

For more information, please contact Jill Sherman at intl.research@lakeheadu.ca.

External Deadline: 
Friday, May 26, 2023
Funding Source: 
External
Funding Level: 
Research